trending Market Intelligence /marketintelligence/en/news-insights/trending/zFHr3gpQmKJTgmbw1uBM8w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Marinus raises $70M from common stock offering, private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Marinus raises $70M from common stock offering, private placement

Marinus Pharmaceuticals Inc. said it raised approximately $70 million from a private and a public offering after underwriters of its previously announced offering fully exercised their overallotment option.

The Radnor, Pa.-based pharmaceutical company sold 32,200,000 shares at $1.25 apiece, including the additional 4,200,000 shares as part of underwriters' overallotment option.

The gross proceeds of $70 million includes a concurrent purchase of up to $30 million of the company's common stock by private investors.

Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. were the joint book-running managers for the offering, while Craig-Hallum Capital Group LLC acted as co-manager.

The company aims to use the net proceeds to develop its experimental drug ganaxolone for rare seizure disorders. The drug failed to beat the placebo in the second part of a mid-stage clinical trial in postpartum depression in July.